Share this video  

ESMO Breast 2020 | HER2 blockade in HER2-E induces low-proliferative luminal A phenotype

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discussed the phenotypic changes of HER2+ breast cancer during and after dual HER2 blockade. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).